Abstracts tagged "AA-amyloidosis"

Abstract Number: 151 • 2017 Pediatric Rheumatology Symposium
Severe Phenotype of Mevalonate-kinase Deficiency in the Czech Republic
Sarka Fingerhutova¹, Lenka Dvorakova², Petr Chrastina², Eva Jancova³, Petra Keslova⁴, Adam Klocperk⁵, Marcel Schuller⁶, Alexander Kolsky⁷ and Pavla Dolezalova¹, ¹Paediatric Rheumatology Unit, General University Hospital in Prague and 1st Faculty of Medicine, Charles University, General University Hospital in Prague and 1st Faculty of Medicine, Prague, Czech Republic, ²Institute of Inherited Metabolic Disorders, Institute of Inherited Metabolic Disorders, 1 st Faculty of Medicine Charles University and General University Hospital in Prague, Prague, Czech Republic, ³Department of Nephrology, General University Hospital in Prague and 1st Faculty of Medicine, Prague, Czech Republic, ⁴Department of Paediatric Haematology and Oncology, 2 nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, 2 nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic, ⁵Department of Immunology, 2 nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, 2 nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic, ⁶Paediatric Rheumatology Unit, University Hospital Brno, Brno, Czech Republic, ⁷Department of Children and Adolescents, 3 rd Faculty od Medicine, Charles University in Prague, Prague, Czech Republic
Background/Purpose: Disease phenotype of mevalonate-kinase (MVK) deficiency (MKD) varies in relation to the extent of enzymatic activity reduction. It ranges from multi-organ involvement with fatal…
Abstract Number: 1196 • 2016 ACR/ARHP Annual Meeting
AA Amyloidosis: An Evaluation of Epidemiology and Prevalence in the US and EU5 Countries
WIlliam Andrews¹, Denis Garceau², Tomascz Sablinski³, Paul Zhang⁴ and Todd Waldman⁴, ¹Auven Therapeutics, Hopkinton, MA, ²Auven Therapeutics, Montreal, QC, Canada, ³Auven Therapeutics, St. Thomas, Virgin Islands (U.S.), ⁴Navigant Consulting, Inc., New York City, NY
Background/Purpose: AA amyloidosis (AAA) is a rare, systemic form of amyloidosis, which mostly occurs secondary to chronic inflammatory conditions, predominantly systemic arthritides. AAA is characterized…
Abstract Number: 1468 • 2014 ACR/ARHP Annual Meeting
Mechanism of Effectiveness of IL-6 Blockade for Reduction of SAA Production and Amyloid a Deposition in AA Amyloidosis Patients with RA
Kazuyuki Yoshizaki, Osaka University, Osaka, Japan
Background/Purpose AA amyloidosis is a serious complication of chronic inflammatory and infectious diseases resulting from the deposition of amyloid A protein. Serum amyloid A (SAA),…
Abstract Number: 1207 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Tocilizumab In Patients With AA Amyloidosis Secondary To Familial Mediterranean Fever: A Single Centre Experience
Sedat Yilmaz¹, Muhammet Cinar², Ismail Simsek¹, Hakan Erdem³ and Salih Pay³, ¹Gulhane School of Medicine, Ankara, Turkey, ²Rheumatology, Gulhane School of Medicine, Ankara, Turkey, ³Division of Rheumatology, Gulhane School of Medicine, Ankara, Turkey
Background/Purpose: The most frequent underlying diseases responsible for AA amyloidosis worldwide are rheumatoid arthritis, juvenile idiopathic arthritis and ankylosing spondylitis, while familial Mediterranean fever (FMF)…
Abstract Number: 431 • 2012 ACR/ARHP Annual Meeting
Basic and Clinical Significance of Interleukin 6 (IL-6) in AA Amyloidosis with RA
Kazuyuki Yoshizaki, Prabha Tiwari, Lokesh P. Tripathi, Shandar Ahmad, Kenji Mizuguchi, Teppei Nishikawa-Matsumura, Tomoyasu Isobe and Soken-Nakazawa J. Song, Osaka University, Osaka, Japan
Background/Purpose: Cytokine-induced hepatic serum amyloid A (SAA) is associated with the pathogenesis of AA amylodosis, a fatal disease with deposition of AA amyloid fibril on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].